CXCL4 drives fibrosis by promoting several key cellular and molecular processes
0301 basic medicine
Epithelial-Mesenchymal Transition
systemic sclerosis
Pulmonary Fibrosis
General Biochemistry,Genetics and Molecular Biology
Platelet Factor 4
Cell Line
Bleomycin
Mice
03 medical and health sciences
SDG 3 - Good Health and Well-being
Human Umbilical Vein Endothelial Cells
Animals
Humans
Myofibroblasts
Lung
Mice, Knockout
Mice, Inbred BALB C
Scleroderma, Systemic
bleomycin
fibrosis
Endothelial Cells
CXCL4
myofibroblast
endothelial-to-mesenchymal transition
Extracellular Matrix
3. Good health
Mice, Inbred C57BL
Disease Models, Animal
inflammation
Collagen
Pericytes
DOI:
10.1016/j.celrep.2021.110189
Publication Date:
2022-01-04T15:45:29Z
AUTHORS (26)
ABSTRACT
Fibrosis is a major cause of mortality worldwide, characterized by myofibroblast activation and excessive extracellular matrix deposition. Systemic sclerosis is a prototypic fibrotic disease in which CXCL4 is increased and strongly correlates with skin and lung fibrosis. Here we aim to elucidate the role of CXCL4 in fibrosis development. CXCL4 levels are increased in multiple inflammatory and fibrotic mouse models, and, using CXCL4-deficient mice, we demonstrate the essential role of CXCL4 in promoting fibrotic events in the skin, lungs, and heart. Overexpressing human CXCL4 in mice aggravates, whereas blocking CXCL4 reduces, bleomycin-induced fibrosis. Single-cell ligand-receptor analysis predicts CXCL4 to affect endothelial cells and fibroblasts. In vitro, we confirm that CXCL4 directly induces myofibroblast differentiation and collagen synthesis in different precursor cells, including endothelial cells, by stimulating endothelial-to-mesenchymal transition. Our findings identify a pivotal role of CXCL4 in fibrosis, further substantiating the potential role of neutralizing CXCL4 as a therapeutic strategy.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (98)
CITATIONS (52)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....